Back to results
US 10,208,017 B2Granted
Heterocycles capable of modulating T-cell responses, and methods of using same
AssigneeNogra Pharma Limited
InventorsDaan Hommes, Auke Verhaar, Gijs Van den Brink, Francesca Viti
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed in part to heterocycles, and their use in treating medical disorders, such as immune inflammatory disorders such as Crohn's disease, ulcerative colitis, rheumatic disorders, psoriasis, and allergies. The compounds are contemplated to modulate T-Cell responses.
Claims10
A method of treating an immune inflammatory disease or disorder in a subject in need thereof, the method comprising administering to the subject a pharmaceutically effective amount of a compound having the formula:
- or a pharmaceutically acceptable salt thereof,
- wherein the immune inflammatory disease or disorder is selected from the group consisting of Crohn's disease, ulcerative colitis, a rheumatic disorder, psoriasis, and an allergy.
A pharmaceutical composition comprising:
- a heterocyclic compound having the formula:
- or a pharmaceutically acceptable salt thereof;
- and
- a pharmaceutically acceptable adjuvant or excipient, wherein the heterocyclic compound is present in a therapeutically effective amount in the pharmaceutical composition.
1 more element
Dependencies are inferred from the claim text.